427 related articles for article (PubMed ID: 31395785)
1. A dominant-negative effect drives selection of
Boettcher S; Miller PG; Sharma R; McConkey M; Leventhal M; Krivtsov AV; Giacomelli AO; Wong W; Kim J; Chao S; Kurppa KJ; Yang X; Milenkowic K; Piccioni F; Root DE; Rücker FG; Flamand Y; Neuberg D; Lindsley RC; Jänne PA; Hahn WC; Jacks T; Döhner H; Armstrong SA; Ebert BL
Science; 2019 Aug; 365(6453):599-604. PubMed ID: 31395785
[No Abstract] [Full Text] [Related]
2. Limited importance of the dominant-negative effect of TP53 missense mutations.
Stoczynska-Fidelus E; Szybka M; Piaskowski S; Bienkowski M; Hulas-Bigoszewska K; Banaszczyk M; Zawlik I; Jesionek-Kupnicka D; Kordek R; Liberski PP; Rieske P
BMC Cancer; 2011 Jun; 11():243. PubMed ID: 21668955
[TBL] [Abstract][Full Text] [Related]
3. A Gain-of-Function p53-Mutant Oncogene Promotes Cell Fate Plasticity and Myeloid Leukemia through the Pluripotency Factor FOXH1.
Loizou E; Banito A; Livshits G; Ho YJ; Koche RP; Sánchez-Rivera FJ; Mayle A; Chen CC; Kinalis S; Bagger FO; Kastenhuber ER; Durham BH; Lowe SW
Cancer Discov; 2019 Jul; 9(7):962-979. PubMed ID: 31068365
[TBL] [Abstract][Full Text] [Related]
4. Mutational processes shape the landscape of TP53 mutations in human cancer.
Giacomelli AO; Yang X; Lintner RE; McFarland JM; Duby M; Kim J; Howard TP; Takeda DY; Ly SH; Kim E; Gannon HS; Hurhula B; Sharpe T; Goodale A; Fritchman B; Steelman S; Vazquez F; Tsherniak A; Aguirre AJ; Doench JG; Piccioni F; Roberts CWM; Meyerson M; Getz G; Johannessen CM; Root DE; Hahn WC
Nat Genet; 2018 Oct; 50(10):1381-1387. PubMed ID: 30224644
[TBL] [Abstract][Full Text] [Related]
5. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database.
Petitjean A; Mathe E; Kato S; Ishioka C; Tavtigian SV; Hainaut P; Olivier M
Hum Mutat; 2007 Jun; 28(6):622-9. PubMed ID: 17311302
[TBL] [Abstract][Full Text] [Related]
6. Combination of Proteasome and Histone Deacetylase Inhibitors Overcomes the Impact of Gain-of-Function p53 Mutations.
Meng X; Yang S; Li Y; Li Y; Devor EJ; Bi J; Wang X; Umesalma S; Quelle DE; Thiel WH; Thiel KW; Leslie KK
Dis Markers; 2018; 2018():3810108. PubMed ID: 30647797
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemistry screening for TP53 mutation in myeloid neoplasms in AZF-fixed bone marrow biopsies.
Yang G; Anderson Williams S; He F; He Y; McIntyre K; Beckman AK; Nelson AC; Yohe SL
Pathology; 2024 Apr; 56(3):404-412. PubMed ID: 38341302
[TBL] [Abstract][Full Text] [Related]
8. Mutant p53 oncogenicity: dominant-negative or gain-of-function?
Stein Y; Aloni-Grinstein R; Rotter V
Carcinogenesis; 2020 Dec; 41(12):1635-1647. PubMed ID: 33159515
[TBL] [Abstract][Full Text] [Related]
9. Human pluripotent stem cells recurrently acquire and expand dominant negative P53 mutations.
Merkle FT; Ghosh S; Kamitaki N; Mitchell J; Avior Y; Mello C; Kashin S; Mekhoubad S; Ilic D; Charlton M; Saphier G; Handsaker RE; Genovese G; Bar S; Benvenisty N; McCarroll SA; Eggan K
Nature; 2017 May; 545(7653):229-233. PubMed ID: 28445466
[TBL] [Abstract][Full Text] [Related]
10. Differences in somatic TP53 mutation type in breast tumors by race and receptor status.
Pollock NC; Ramroop JR; Hampel H; Troester MA; Conway K; Hu JJ; Freudenheim JL; Olopade OI; Huo D; Ziv E; Neuhausen SL; Stevens P; McElroy JP; Toland AE
Breast Cancer Res Treat; 2022 Apr; 192(3):639-648. PubMed ID: 35286522
[TBL] [Abstract][Full Text] [Related]
11. Presence of mutant p53 increases stem cell frequency and is associated with reduced binding to classic TP53 binding sites in cell lines and primary AMLs.
Gerritsen M; Hilgendorf S; Yi G; Wierenga ATJ; Schuringa JJ; Martens JHA; Vellenga E
Exp Hematol; 2022 Jun; 110():39-46. PubMed ID: 35315319
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of glucosylceramide synthase eliminates the oncogenic function of p53 R273H mutant in the epithelial-mesenchymal transition and induced pluripotency of colon cancer cells.
Hosain SB; Khiste SK; Uddin MB; Vorubindi V; Ingram C; Zhang S; Hill RA; Gu X; Liu YY
Oncotarget; 2016 Sep; 7(37):60575-60592. PubMed ID: 27517620
[TBL] [Abstract][Full Text] [Related]
13. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
[TBL] [Abstract][Full Text] [Related]
14. TP53 gain-of-function mutation promotes inflammation in glioblastoma.
Ham SW; Jeon HY; Jin X; Kim EJ; Kim JK; Shin YJ; Lee Y; Kim SH; Lee SY; Seo S; Park MG; Kim HM; Nam DH; Kim H
Cell Death Differ; 2019 Mar; 26(3):409-425. PubMed ID: 29786075
[TBL] [Abstract][Full Text] [Related]
15. The role of TP53 in acute myeloid leukemia: Challenges and opportunities.
Barbosa K; Li S; Adams PD; Deshpande AJ
Genes Chromosomes Cancer; 2019 Dec; 58(12):875-888. PubMed ID: 31393631
[TBL] [Abstract][Full Text] [Related]
16. Germline TP53 mutations result into a constitutive defect of p53 DNA binding and transcriptional response to DNA damage.
Zerdoumi Y; Lanos R; Raad S; Flaman JM; Bougeard G; Frebourg T; Tournier I
Hum Mol Genet; 2017 Jul; 26(14):2591-2602. PubMed ID: 28369373
[TBL] [Abstract][Full Text] [Related]
17. Lung-Enriched Mutations in the p53 Tumor Suppressor: A Paradigm for Tissue-Specific Gain of Oncogenic Function.
Barta JA; McMahon SB
Mol Cancer Res; 2019 Jan; 17(1):3-9. PubMed ID: 30224539
[TBL] [Abstract][Full Text] [Related]
18. Drastic effect of germline TP53 missense mutations in Li-Fraumeni patients.
Zerdoumi Y; Aury-Landas J; Bonaïti-Pellié C; Derambure C; Sesboüé R; Renaux-Petel M; Frebourg T; Bougeard G; Flaman JM
Hum Mutat; 2013 Mar; 34(3):453-61. PubMed ID: 23172776
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of TP53 mutations and single nucleotide polymorphisms in acute myeloid leukemia: a case series and literature review.
Zeichner SB; Alghamdi S; Elhammady G; Poppiti RJ
Asian Pac J Cancer Prev; 2014; 15(4):1603-9. PubMed ID: 24641375
[TBL] [Abstract][Full Text] [Related]
20. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
